Potential for combined therapy with 348u87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir‐resistant herpes simplex virus infection

S. Safrin, T. Schacker, J. Delehanty, E. Hill, L. Corey

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Fingerprint

Dive into the research topics of 'Potential for combined therapy with 348u87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir‐resistant herpes simplex virus infection'. Together they form a unique fingerprint.

Medicine & Life Sciences